Marinus is a new specialty pharmaceutical company dedicated to the development and commercialization of novel drugs to treat serious neurological, psychiatric, and pain disorders.

Ganaxolone

A new drug for the treatment of both adult and pediatric epilepsy. Ganaxolone is being studied in adult complex partial seizures. In children, ganaxolone is being studied as a treatment for infantile spasms, a catastrophic pediatric epilepsy
more»

Chelerythrine

**Announcements**

MARINUS PHARMACEUTICALS APPOINTS JOHN KRAYACICH AS PRESIDENT AND CHIEF EXECUTIVE OFFICER

BRANFORD, CT – August 5, 2008 – Marinus Pharmaceuticals, a developer of specialty therapeutics to treat serious neurological, psychiatric and pain disorders, has appointed John Krayacich as president and chief executive officer. more»

MARINUS PHARMACEUTICALS INITIATES PHASE IIB STUDY OF GANAXOLONE FOR ADULT PARTIAL SEIZURES

BRANFORD, CT – May 4, 2007 – Marinus Pharmaceuticals, Inc. announces that it is enrolling patients in an international, multi-center, placebo controlled Phase IIb study of its lead compound, Ganaxolone, as an adjunctive treatment in adults suffering from partial onset seizures. more»

MARINUS PHARMACEUTICALS INITIATES PHASE IIB STUDY OF GANAXOLONE FOR INFANTILE SPAMS

BRANFORD, CT – February 27, 2007 – Marinus Pharmaceuticals, Inc. announces the dosing of the first patient in an international, multi-center, randomized Phase IIb study of its lead compound, ganaxolone, in infants suffering from Infantile Spasms (also called West syndrome), an indication for which the company has received an Orphan Drug designation from the U.S. Food and Drug Administration (FDA). more»

NEW GANAXOLONE FORMULATION

October 2006 – Marinus advances new ganaxolone formulation that resolves historic PK and Cost of Goods issues. Announces clinical trials of ganaxolone for infantile spasms and adult partial complex seizure syndrome more»